Ewing's sarcoma and primitive neuroectodermal tumour (ES/PNET) presenting as a breast mass

SUEBWONG CHUTHAPISITH¹, WILAIRAT PRASERT¹, MALEE WARNNISSORN², KANAPON PRADNIWAT², VICHIEH SRIMUNINNIMIT³ and TAMNIT ANGSUSINHA⁴

Departments of ¹Surgery, ²Pathology and ³Medicine; ⁴Thanyarak Breast Imaging Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok 10700, Thailand

Received February 9, 2012; Accepted April 24, 2012

DOI: 10.3892/ol.2012.698

Abstract. Ewing's sarcoma/primitive neuroectodermal tumour (ES/PNET) is a rare tumour usually detected in young individuals and uncommonly found within the breast tissue. In this case report, we examined a 46-year-old patient, who developed a lump on her breast and was later diagnosed with ES/PNET. Clinical presentation, age at development and radiological findings were of interest and were discussed. Diagnosis of the tumour was confirmed using various immunohistochemical studies and the presence of a translocation, t(11;22). A literature review of this rare condition was also included.

Introduction

Ewing's sarcoma/primitive neuroectodermal tumour (ES/PNET) is a member of the Ewing's sarcoma family of tumours (ESFT). Extraskeletal ES is a manifestation of ES within the soft tissues, and an ES tumour presenting as a breast mass is unusual. ES typically occurs in adolescents and young adults aged between 10 and 20 years (1). The diagnosis of ES/PNET requires panels of immunohistochemical study and the presence of a t(11;22) translocation detected through fluorescent in situ hybridization (FISH). This case report examines a rare case of ES/PNET observed in a 46-year-old woman, who developed a painless and progressive tumour presenting as a breast mass. The patient's family provided their consent to the study.

Case report

In 2010, a 46-year-old woman presented a painless and progressive mass in her right breast for 1 month. Upon diagnostic mammography and ultrasonography, a suspicious mass of 4 cm in size was identified (Fig. 1A and B). Following this, a biopsy was performed and the initial diagnosis was a neuroendocrine carcinoma, as the tumour was positive for synaptophysin, but negative for ER, PR, HER2/neu and CK8/18.

Following a core needle biopsy, the tumour increased rapidly in size and became 12x12 cm within 1 month. The patient received chemotherapy containing cyclophosphamide, adriamycin and vincristine for 6 cycles, to which the tumour responded well and shrank to 1.5x2.5 cm. Whole breast radiation was continued at a dose of 50 Gy; however, following completion, the tumour progressed quickly to 6x7 cm within 1 month. A CT scan of the chest revealed a 0.6 cm sized nodule in the right lung. Therefore, platinum and etoposide were commenced for 3 cycles, followed by paclitaxel and carboplatin. Despite this treatment, the tumour did not respond to the chemotherapy administered and the disease progressed; the patient was then referred to our institute.

While the patient was in our institute, the tumour invaded through the skin and grew to 20x15 cm. A review of a previous biopsy demonstrated ES/PNET as a malignant small round cell neoplasm (Fig. 2A). Immunohistochemical staining was performed for vimentin (clone V9, dilution 1:500), CD20 (clone L26, dilution 1:2,000), CD99 (clone 12E7, ready-to-use), desmin (clone D33, dilution 1:1,000), S-100 (polyclonal, dilution 1:10,000) from DakoCytomation (Glostrup, Denmark); FLI-1 (clone MRQ-1, ready-to-use), CD56 (clone 123C3.D5, ready-to-use), AE1/AE3 (ready-to-use), chromogranin A (LK2H10, ready-to-use), CD30 (clone Ber-H2, ready-to-use) from Cell Marque (Rocklin, CA, USA); CD5 (clone 123C3.D5, ready-to-use), AE1/AE3 (ready-to-use), chromogranin A (LK2H10, ready-to-use), CD30 (clone Ber-H2, ready-to-use) from Cell Marque (Rocklin, CA, USA); CD5 (clone 5D3, dilution 1:300) from NEOMARKERS (Fremont, CA, USA); synaptophysin (clone SP11, dilution 1:500) from Diagnostic Biosystems (Pleasanton, CA, USA); CD45 (clone PD7/26/16&2B11, dilution 1:2,000) from BioGenex (Fremont, CA, USA); CD3 (clone LN10, ready-to-use), TdT (clone NPT26, ready-to-use), TTF-1 (clone SPT24, ready-to-use) from Novocastra (Newcastle, UK) and Pax-5 (clone SP34, ready-to-use)
from Ventana (Tucson, AZ, USA). An automated immunostainer, BenchMark XT (Ventana), with a polymer-based DakoEnVision detection system (DakoCytomation), were used. The tumour cells marked with vimentin, FLI-1 (diffuse nuclear staining), CD99 (membrane staining; intense) and CD56 were negative for desmin, AE1/AE3, CK8/18, chromogranin A, synaptophysin, S100, CD45, CD3, CD20, PAX5, CD30, TdT and TTF-1 (Fig. 2B and C). These results were consistent with ES/PNET. Following this, two cycles of paclitaxel and carboplatin were initiated. Progression of the disease was observed and a modified radical mastectomy with local skin flap coverage was performed (Fig. 3A and B). The tumour was localized in the upper outer part of the right breast, with involvement of the underlying skeletal muscle, measuring 20.5x15.5x12 cm. The surgical margins were free from the tumour, and lymphovascular invasion and metastasis to the axillary lymph nodes (3 of 24 nodes), were reported. An additional FISH study confirmed the presence of EWSR1 gene translocation (Fig. 2D). Thus, ES/PNET was the final diagnosis.

Only 1 month following the surgery, the patient developed recurrent disease on the chest wall, as well as multiple lung nodules. The disease progressed rapidly and two months following surgery, the patient succumbed to respiratory failure due to pulmonary metastasis.

Discussion

We report a rare case of extraskeletal ES/PNET, presenting with a rapidly growing palpable breast lump. Age at presentation, radiological findings and immunohistochemical findings were of interest and documented in this report.

ES and PNET are typically undifferentiated (1,2). Translocation t(11;22)(q24;q12) resulting in EWS/FLI1 fusion, which can be identified in more than 90% of ES/PNET cases, is the genetic hallmark of ES/PNET (3). In cases with classic morphology where other small round cell neoplasms have been excluded immunohistochemically, the expression of CD99 cell surface antigen (product of the MIC-2 gene) is required to support ES/PNET diagnosis (4,5).

The majority of patients with ES/PNET are 10-20 years old (1), and other small studies of adult ES/PNET from the Royal Marsden, the Memorial Sloan-Kettering and the Dana-Faber Cancer Centers have reported a median age of 24-27 years (1,6,7). However, our patient was 46 years of age at the time of diagnosis, which is unusual.
ES/PNET development within breast tissue was unlikely to be diagnosed upon first presentation. Findings from mammography and ultrasonography breast images may vary as they could be from a hypoechoic mass with posterior enhancement or heterogeneous mass with a necrotic area (8,9). In this patient, a well-circumscribed mass was documented (Fig. 1A and B), which possibly arose from the soft tissue beneath the breast. Precise identification of the tumour location (chest wall soft tissue) and recognition of variation in radiographic findings described in this tumour may be a clue for radiologists to avoid misinterpreting the tumour as a breast mass that might preclude the diagnosis of soft tissue tumours.

Diagnosis of ES/PNET in this patient was based on the immunohistochemical staining results, which documented a positive expression of CD56, CD99, FLI-1, synaptophysisin and vimentin, but a negative expression of AE1/AE3, CK8/18, EMA, chromogranin A, CD45 (LCA), HER-2, ER and PR. An additional FISH study confirmed the presence of EWSRI gene translocation. The positive expression of CD99 (MIC2), a cell surface glycoprotein involved in cell adhesion, plays a crucial role in the diagnosis of ES/PNET (10). However, CD99 may also be expressed in other tumours, including metastatic carcinoma of the breast, neuroendocrine carcinoma, lymphoma and rhabdomyosarcoma (11). In our patient, small cell carcinoma, neuroendocrine carcinoma and malignant lymphoma were excluded by negative staining for cytokeratins, chromogranin A and LCA.

ES/PNET is an aggressive tumour with a high incidence of local recurrence and distant metastasis. A combination of multiple modalities, including surgery, chemotherapy and radiation therapy, was the most appropriate treatment for our patient (1). All members of the ESFT tend to share the propensity for metastatic spread. Consistent use of systemic chemotherapy to treat localised ESFT effectively improved the 5-year survival rate from 5 to 10% up to 65%, which is primarily due to the elimination of micrometastases (12-14). Although the optimum combination chemotherapy has not yet been established, a regimen containing vincristine, adriamycin, cyclophosphamide and actinomycin D, was the standard first-line treatment for patients with localized disease (12). In patients with unresectable or metastatic disease, palliative chemotherapy may be useful. In this patient, vincristine, adriamycin and cyclophosphamide were utilized at the first instance. The tumour appeared to respond well initially, but became resistant to various chemotherapeutic agents, which resulted in progression of the disease.

The role of radiation therapy in the treatment of ES/PNET is unclear. However, the use of radiation therapy combined with surgery, in order to control local disease, is proving to be helpful (1). Our patient did not respond to radiation therapy treatment and the tumour grew rapidly following cessation of radiation. This is similar to a previous study where a 78% disease progression rate was observed in 14 patients treated with radiotherapy plus chemotherapy (15).

In conclusion, we report a rare case of ES/PNET presenting as a breast mass. Clinical presentation mimicked invasive breast cancer. The tumour did not respond well to multimodality treatment and local and distant metastasis occurred less than 2 years after first diagnosis.

References